Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption

Dermatology

Volumn 224, Issue 3, 2012, Pages 224-227

  Mller, P A ^a   Brcker, E B ^a   Klinker, E ^a   Stoevesandt, J ^a   Benoit, S ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Bullous pemphigoid; Immunoadsorption; Immunoapheresis

Indexed keywords

AUTOANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN A;

ADJUVANT CHEMOTHERAPY; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BULLOUS PEMPHIGOID; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG DOSE REDUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOADSORPTION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; AUTOANTIBODIES; AUTOANTIGENS; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYCOPHENOLIC ACID; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; SORPTION DETOXIFICATION; STAPHYLOCOCCAL PROTEIN A; TREATMENT OUTCOME;

EID: 84863777059     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000339071     Document Type: Article

References (11)

1. Kromminga A, Scheckenbach C, Georgi M, Hagel C, Arndt R, Christophers E, Bröcker EB, Zillikens D: Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180 and IgG autoimmune response to BP180. J Autoimmun 2000; 15: 293-300.
2. Kirtschig G, Middleton P, Bennet C, Murrell DF, Wojnarowska F, Khumalo NP: Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; 6:CD002292.
3. Schmidt E, Zillikens D: Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241-253.
4. Zillikens D, Derfler K, Emig R, Fierlbeck G, Goebeler M, Hertl M, Hofmann SC, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, Schmidt E, Shimanovich I, Michael M, Ziller F: Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2008; 6: 881-887.
5. Braun N, Bosch T: Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 2000; 9: 2017-2038.
6. Kasperkiewicz M, Meier M, Zillikens D, Schmidt E: Successful application of immunoadsorption and review of the literature. Dermatology 2010; 220: 259-263.
7. Ino N, Kamata N, Matsuura C, Shinkai H, Okada M: Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1997; 1: 372-376.
8. Herrero-Gonzalez JE, Sitaru C, Klinker E, Bröcker EB, Zillikens D: Successful adjuvant treatment of severe bullous pemphigoid by trytptophan immunoadsortion. Clin Exp Dermatol 2005; 30: 519-522.
9. Biesenbach P, Schmaldienst S, Smolen JS, Hörl WH, Derfler K, Stummvoll GH: Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atheroscler Suppl 2009; 10: 114-121.
10. Matic G, Hofmann D, Winkler R, Tiess M, Michelsen A, Schneidewind JM, Hebestreit G, Keysser M, Müller W, Kinze EM, Ramlow W: Removal of immunoglobulins by protein A versus an antihuman immunoglobulin Gbased system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000; 24: 103-107.
11. Schmaldienst S, Müllner M, Goldammer A, Spitzauer S, Banyai S, Hörl WH, Derfler K: Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology 2001; 40: 513-521.